To validate the interaction modification of FOXO1 and CDK2 in GBM cells, endogenous FOXO1 proteins were subjected to IP assay with FOXO1 antibody and immunoblotted with ubiquitin and CDK2 antibodies. This evidence concerns the gene FOXO1 and glioblastoma.